. Author manuscript; available in PMC: 2017 May 1.

Published in final edited form as: Cancer Prev Res (Phila). 2016 Mar 7;9(5):396–405. doi: 10.1158/1940-6207.CAPR-15-0380

Table 3.

Urinary levels of [pyridine-D₄]NNK metabolites by PEITC treatment, The PEITC Intervention Study 2008–2013

Urinary metabolites of [pyridine-D₄]NNK	Geometric mean [pmol/mg creatinine]
Urinary metabolites of [pyridine-D₄]NNK	Placebo (n= 82)	PEITC (n=82)	% difference (95% CI)	P for difference^a
Total [pyridine-D₄]NNAL (pmol/mg creatinine)	0.336	0.336	−0.1 (−8.5, 9.1)	0.980
[pyridine-D₄]Hydroxy acid (pmol/mg creatinine)	0.150	0.140	−6.7 (−13.8, 1.0)	0.092
[pyridine-D₄]Hydroxy acid: [pyridine-D₄] total NNAL ratio	0.455	0.420	−7.7 (−13.8, −1.2)	0.023

2-sided P values were for PEITC treatment effect and derived from the mixed model.